Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1CNS 1Breast 1

Conditions

Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 147Radiotherapy 90Cyclophosphamide 53Magnetic Resonance Spectroscopy 42Radiation 41Bevacizumab 38Irinotecan 34Filgrastim 29Radiosurgery 26Specimen Handling 25Nivolumab 25Carboplatin 24Topotecan 23Etoposide 22fludarabine 20Surgical Procedures, Operative 20pembrolizumab 18Vorinostat 18Vincristine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17sargramostim 15Peripheral Blood Stem Cell Transplantation 14Ipilimumab 14Drug Therapy 13temsirolimus 12Sirolimus 12Radiotherapy, Intensity-Modulated 12O(6)-benzylguanine 12Everolimus 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Microarray Analysis × CNS × Clear all
NCT00387400 2023-08-04

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Canadian Cancer Trials Group

Phase 1 Completed
32 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡